Impact of Adipose Tissue in COVID-19

Overview

Overweight or obese patients are particularly exposed to severe forms of COVID-19. Few data suggest that adipose tissue infected with SARS-CoV-2 could be involved in the onset of the cytokine storm seen in severe forms of COVID-19. The aim of this study is to determine the pathogenesis of SARS-CoV-2-infection of adipose tissue. In particular the investigators will study how this virus enters the adipocyte and how it modulates metabolism and inflammation in the adipose tissue. From these data, the investigators hope to determine at the adipose tissue level, original therapeutic targets to modulate the effects of SARS-CoV-2 at the systemic level.

Full Title of Study: “Impact of Adipose Tissue in COVID-19 : From Pathophysiology to Therapeutic Perspectives”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 22, 2021

Interventions

  • Other: Adipose tissue
    • Adipose tissue sampling

Arms, Groups and Cohorts

  • Obese or overweight patients
  • Patients without overweight

Clinical Trial Outcome Measures

Primary Measures

  • Comparison of the expression of ACE2 and TMPRSS2 in the subcutaneous and visceral adipose tissue of obese patients. Determination of cells expressing ACE2 and TMPRSS2 in whole human adipose tissue.
    • Time Frame: 12 months
    • Analysis of the expression of mRNA and ACE2 and TMPRSS2 proteins in the subcutaneous and visceral adipose tissue of normal weight and obese patients

Secondary Measures

  • Demonstration of entry and replication of SARS-CoV-2 in human adipose tissue
    • Time Frame: 12 months
    • Infection of human adipocytes in lean and obese subjects by SARS-CoV-2
  • Consequences of infection with SARS-CoV-2 on the metabolism and inflammatory state of adipose tissue.
    • Time Frame: 12 months
    • Assessment of the expression and secretion of inflammatory cytokines (TNF-α, IL-1 , IL-4 , IL-6 , IL-7 , IL-10 , IL-12 , IL-13 , IL-18 ¸ IL-23, INF-α, INF-β) after infection with SARS-CoV-2 of adipose tissue / adipocytes of thin and obese subjects. Evaluation of SARS-CoV-2 infection on the lipolysis of adipose tissue / adipocytes in thin and obese subjects.
  • Consequences of infection with SARS-CoV-2 on the metabolism and inflammatory state of adipose tissue.
    • Time Frame: 12 months
    • Evaluation of SARS-CoV-2 infection on the lipolysis of adipose tissue / adipocytes in thin and obese subjects.
  • Effect of SARS-CoV-2 infection of adipose tissue / adipocytes from thin and obese subjects on endoplasmic reticulum (ER) homeostasis.
    • Time Frame: 12 months
    • Study whether infection with SARS-CoV-2 activates the RE stress pathways in adipose tissue
  • Target endoplasmic reticulum stress to reduce spread of SARS-CoV-2 from adipose tissue
    • Time Frame: 12 months
    • Use of RE stress inhibitors on adipocytes infected with SARS-CoV-2 and assess their effect on the maturation of the virus in infected cells.

Participating in This Clinical Trial

Inclusion Criteria

  • Age greater than or equal to 18 years – All patients who are obese or overweight (> 25 kg/m2) or non-obese (< or = 25 kg/m2) operated for abdominal vascular surgery – Beneficiary or entitled to a social security scheme (except AME) Exclusion Criteria:
  • Pregnant or breastfeeding woman – Patient refusal – Patient deprived of liberty or subject to a legal protection measure (guardianship, curatorship)
  • Gender Eligibility: All

    Minimum Age: 18 Years

    Maximum Age: N/A

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • Assistance Publique – Hôpitaux de Paris
    • Provider of Information About this Clinical Study
      • Sponsor
    • Overall Official(s)
      • Olivier BOURRON, Dr, Principal Investigator, Hôpital Pitié Salpêtrière – Assistance Publique Hôpitaux de Paris
    • Overall Contact(s)
      • Olivier BOURRON, Dr, 0142178118, olivier.bourron@aphp.fr

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.